Blood test–guided sunitinib or regorafenib for GIST
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have confirmed GIST that is metastatic (spread) or cannot be removed by surgery.
- You previously took imatinib (and either it stopped working, didn’t help enough, or you couldn’t tolerate it).
- Your health/strength is good enough (ECOG 0 to 2).
- A ctDNA blood test (or biopsy) shows a KIT mutation in exon 13 or 17.
- You have not previously taken sunitinib or regorafenib, and you have had no more than 2 prior targeted TKI drug treatment “regimens.”
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
This study tests a new drug called DCC-2618 for patients with GIST (a rare stomach/intestinal cancer) who have already tried at least three other treatments. The goal is to see if this drug can slow or shrink tumors in patients whose cancer has stopped responding to standard medications.
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
This study tests a combination of two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—for people with advanced GIST whose tumors have a specific KIT gene mutation (exon 17) and have stopped responding to standard treatments.
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.